Skip to main navigation Skip to search Skip to main content

Barriers and Strategies for Oral Peptide and Protein Therapeutics Delivery: Update on Clinical Advances

  • Kangwon National University
  • NVience Inc.

Research output: Contribution to journal › Review article › peer-review

127 Scopus citations

Abstract

Peptide and protein (PP) therapeutics are highly specific and potent biomolecules that treat chronic and complex diseases. However, their oral delivery is significantly hindered by enzymatic degradation, instability, and poor permeability through the gastrointestinal (GI) epithelium, resulting in low bioavailability. Various strategies have emerged as transformative solutions to address existing challenges, offering enhanced protection, stabilization, and absorption of PPs. These strategies primarily focus on two major challenges: protecting the PP against harsh conditions and enhancing permeation across the intestinal membrane. Innovative approaches such as pH modulation and incorporation of enzyme inhibitors are usually used to mitigate proteolytic degradation of PP during transit across the GI tract. In a similar vein, absorption enhancers and prodrug strategies facilitate epithelial transport, while targeted delivery systems focus on specific areas of the GI tract to enhance absorption. Likewise, mucus-penetrating and mucoadhesive strategies have enhanced retention and interaction with epithelial cells, effectively overcoming barriers like the mucus layer and tight epithelial junctions. Furthermore, structural modifications such as lipidation, peptide cyclization, and polyethylene glycosylation are promising alternatives to render stability, prolong circulation time, and membrane permeability. In particular, functional biomaterials, active targeting, and lymphatic transport strategies have provided new platforms for oral PP delivery. Advancing in materials science, nanotechnology, and the disruption of medical devices holds new frontiers to overcome barriers. Despite substantial advancements, the limited success in clinical translation underscores the urgency of innovative strategies. This review presents oral PPs as a promising platform, highlighting the key barriers and strategies to transform their therapeutic landscapes.

Original languageEnglish
Article number397
JournalPharmaceutics
Volume17
Issue number4
DOIs
StatePublished - Apr 2025

Keywords

  • bioavailability enhancement
  • enzymatic degradation
  • oral drug delivery
  • protein therapeutics

Fingerprint

Dive into the research topics of 'Barriers and Strategies for Oral Peptide and Protein Therapeutics Delivery: Update on Clinical Advances'. Together they form a unique fingerprint.

Cite this